Loading…
Lobbying Spend
—
Filings
6
Firms Hired
1
Active Period
2023–2024
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
2024 · first_quarter · Firm: TIBER CREEK GROUP
Issues related to Valley fever; H.R. 6227/S.3220 - Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023; H.R. 6731/S.3464, the FORWARD Act.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6227
Issues related to Valley fever; H.R. 6227/S.3220 - Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023; H.R. 6731/S.3464, the FORWARD Act.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6731
A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.
2024 · first_quarter · Firm: TIBER CREEK GROUP
Issues related to Valley fever; H.R. 6227/S.3220 - Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023; H.R. 6731/S.3464, the FORWARD Act.
Client expense: — · Firm income: $30,000
Matched citations: S.3220
Issues related to Valley fever; H.R. 6227/S.3220 - Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023; H.R. 6731/S.3464, the FORWARD Act.
Client expense: — · Firm income: $30,000
Matched citations: S.3464
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
2023 · fourth_quarter · Firm: TIBER CREEK GROUP
Issues related to Valley fever; H.R. 6227/S.3220 - Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023; H.R. 6731/S.3464, the FORWARD Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R. 6227
Issues related to Valley fever; H.R. 6227/S.3220 - Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023; H.R. 6731/S.3464, the FORWARD Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R. 6731
A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.
2023 · fourth_quarter · Firm: TIBER CREEK GROUP
Issues related to Valley fever; H.R. 6227/S.3220 - Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023; H.R. 6731/S.3464, the FORWARD Act.
Client expense: — · Firm income: $80,000
Matched citations: S.3220
Issues related to Valley fever; H.R. 6227/S.3220 - Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023; H.R. 6731/S.3464, the FORWARD Act.
Client expense: — · Firm income: $80,000
Matched citations: S.3464
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
2023 · fourth_quarter · Firm: TIBER CREEK GROUP
H.R.6227 - Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023; S.3220 - A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis; legislation related to Valley fever.
Client expense: — · Firm income: —
Matched citations: H.R.6227
A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.
2023 · fourth_quarter · Firm: TIBER CREEK GROUP
H.R.6227 - Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023; S.3220 - A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis; legislation related to Valley fever.
Client expense: — · Firm income: —
Matched citations: S.3220
Source: Senate LDA